VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8902 USD | +11.27% |
|
+44.23% | +24.16% |
| Apr. 23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
| Mar. 26 | Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8
USD
Average target price
3.725
USD
Spread / Average Target
+365.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.16% | 65.65M | |
| -20.53% | 11.48B | |
| +41.94% | 3.27B | |
| -36.56% | 2.2B | |
| -18.92% | 2.05B | |
| -29.19% | 1.49B | |
| +15.73% | 1.01B | |
| -4.37% | 743M | |
| -37.00% | 413M | |
| -46.73% | 377M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Maxim Group Adjusts Price Target on VolitionRX to $5 From $8, Reiterates Buy Rating
